USRE29032E - 3-Benzoylfluoro-methanesulfonanilides - Google Patents
3-Benzoylfluoro-methanesulfonanilides Download PDFInfo
- Publication number
- USRE29032E USRE29032E US05/632,572 US63257275A USRE29032E US RE29032 E USRE29032 E US RE29032E US 63257275 A US63257275 A US 63257275A US RE29032 E USRE29032 E US RE29032E
- Authority
- US
- United States
- Prior art keywords
- halogen
- iadd
- iaddend
- compound according
- benzoyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 150000001875 compounds Chemical class 0.000 claims abstract description 56
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 14
- 150000001721 carbon Chemical group 0.000 claims abstract description 14
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 14
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 13
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 12
- 125000005843 halogen group Chemical group 0.000 claims abstract description 12
- 150000002367 halogens Chemical class 0.000 claims abstract description 11
- 125000001188 haloalkyl group Chemical group 0.000 claims abstract description 10
- 239000001257 hydrogen Substances 0.000 claims abstract description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 10
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 8
- 150000001768 cations Chemical class 0.000 claims abstract description 8
- 125000003342 alkenyl group Chemical group 0.000 claims abstract description 5
- 125000004438 haloalkoxy group Chemical group 0.000 claims abstract description 5
- 150000002431 hydrogen Chemical group 0.000 claims abstract 5
- 229910052731 fluorine Inorganic materials 0.000 claims description 5
- 239000011737 fluorine Substances 0.000 claims description 5
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 159000000000 sodium salts Chemical class 0.000 claims description 4
- 239000000460 chlorine Substances 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 3
- 101001072067 Homo sapiens Proprotein convertase subtilisin/kexin type 4 Proteins 0.000 claims 1
- 108010022052 Proprotein Convertase 5 Proteins 0.000 claims 1
- 102100036371 Proprotein convertase subtilisin/kexin type 4 Human genes 0.000 claims 1
- 102100036365 Proprotein convertase subtilisin/kexin type 5 Human genes 0.000 claims 1
- 102100038950 Proprotein convertase subtilisin/kexin type 7 Human genes 0.000 claims 1
- 101710180647 Proprotein convertase subtilisin/kexin type 7 Proteins 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000005010 perfluoroalkyl group Chemical group 0.000 claims 1
- 150000003839 salts Chemical class 0.000 abstract description 12
- 239000002260 anti-inflammatory agent Substances 0.000 abstract description 6
- 229940121363 anti-inflammatory agent Drugs 0.000 abstract description 6
- 230000000144 pharmacologic effect Effects 0.000 abstract description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract description 4
- 101001022148 Homo sapiens Furin Proteins 0.000 abstract 1
- 101000701936 Homo sapiens Signal peptidase complex subunit 1 Proteins 0.000 abstract 1
- 102100030313 Signal peptidase complex subunit 1 Human genes 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 30
- OXDSKEQSEGDAFN-UHFFFAOYSA-N 1,1,1-trifluoro-n-phenylmethanesulfonamide Chemical compound FC(F)(F)S(=O)(=O)NC1=CC=CC=C1 OXDSKEQSEGDAFN-UHFFFAOYSA-N 0.000 description 28
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
- 238000000034 method Methods 0.000 description 19
- 239000000203 mixture Substances 0.000 description 16
- 239000000047 product Substances 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 15
- 239000007787 solid Substances 0.000 description 13
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- LBTPIFQNEKOAIM-UHFFFAOYSA-N n-phenylmethanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC=C1 LBTPIFQNEKOAIM-UHFFFAOYSA-N 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 11
- 238000010992 reflux Methods 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- WOPCCJAPUINYMV-UHFFFAOYSA-N 1-fluoro-n-phenylmethanesulfonamide Chemical compound FCS(=O)(=O)NC1=CC=CC=C1 WOPCCJAPUINYMV-UHFFFAOYSA-N 0.000 description 10
- -1 oxy, sulfonyl Chemical group 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 8
- 206010030113 Oedema Diseases 0.000 description 7
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- FUADXEJBHCKVBN-UHFFFAOYSA-N (3-aminophenyl)-phenylmethanone Chemical compound NC1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 FUADXEJBHCKVBN-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 206010015150 Erythema Diseases 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 230000003110 anti-inflammatory effect Effects 0.000 description 6
- 239000003610 charcoal Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 231100000321 erythema Toxicity 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- MAOBFOXLCJIFLV-UHFFFAOYSA-N (2-aminophenyl)-phenylmethanone Chemical compound NC1=CC=CC=C1C(=O)C1=CC=CC=C1 MAOBFOXLCJIFLV-UHFFFAOYSA-N 0.000 description 5
- 238000001704 evaporation Methods 0.000 description 5
- 230000008020 evaporation Effects 0.000 description 5
- 210000002683 foot Anatomy 0.000 description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000001953 recrystallisation Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 3
- 206010030124 Oedema peripheral Diseases 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 150000008064 anhydrides Chemical class 0.000 description 3
- JYQLKKNUGGVARY-UHFFFAOYSA-N difluoromethanesulfonyl chloride Chemical compound FC(F)S(Cl)(=O)=O JYQLKKNUGGVARY-UHFFFAOYSA-N 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- NNINWAWDVUHMGM-UHFFFAOYSA-N fluoromethanesulfonyl chloride Chemical compound FCS(Cl)(=O)=O NNINWAWDVUHMGM-UHFFFAOYSA-N 0.000 description 3
- 210000000548 hind-foot Anatomy 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 230000020477 pH reduction Effects 0.000 description 3
- UJHSIDUUJPTLDY-UHFFFAOYSA-N (2-nitrophenyl)-phenylmethanone Chemical class [O-][N+](=O)C1=CC=CC=C1C(=O)C1=CC=CC=C1 UJHSIDUUJPTLDY-UHFFFAOYSA-N 0.000 description 2
- CXCHEKCRJQRVNG-UHFFFAOYSA-N 2,2,2-trifluoroethanesulfonyl chloride Chemical compound FC(F)(F)CS(Cl)(=O)=O CXCHEKCRJQRVNG-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical group ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 239000002221 antipyretic Substances 0.000 description 2
- 239000007810 chemical reaction solvent Substances 0.000 description 2
- 150000001805 chlorine compounds Chemical class 0.000 description 2
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 2
- 239000012265 solid product Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- UBOXGVDOUJQMTN-UHFFFAOYSA-N trichloroethylene Natural products ClCC(Cl)Cl UBOXGVDOUJQMTN-UHFFFAOYSA-N 0.000 description 2
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
- HNSWHUXOQVJNOH-UHFFFAOYSA-N (3-amino-5-bromophenyl)-phenylmethanone Chemical compound NC1=CC(Br)=CC(C(=O)C=2C=CC=CC=2)=C1 HNSWHUXOQVJNOH-UHFFFAOYSA-N 0.000 description 1
- DXDUVRCTXVJTAI-UHFFFAOYSA-N (3-aminophenyl)-(2-ethoxyphenyl)methanone Chemical compound CCOC1=CC=CC=C1C(=O)C1=CC=CC(N)=C1 DXDUVRCTXVJTAI-UHFFFAOYSA-N 0.000 description 1
- IRPWFLRIVJLGEQ-UHFFFAOYSA-N (3-aminophenyl)-(4-ethoxyphenyl)methanone Chemical compound C1=CC(OCC)=CC=C1C(=O)C1=CC=CC(N)=C1 IRPWFLRIVJLGEQ-UHFFFAOYSA-N 0.000 description 1
- PTGHDQLHRCUGNL-UHFFFAOYSA-N (3-aminophenyl)-(4-ethylphenyl)methanone Chemical compound C1=CC(CC)=CC=C1C(=O)C1=CC=CC(N)=C1 PTGHDQLHRCUGNL-UHFFFAOYSA-N 0.000 description 1
- YELJAOYXDLKMGA-UHFFFAOYSA-N (3-aminophenyl)-(4-fluorophenyl)methanone Chemical compound NC1=CC=CC(C(=O)C=2C=CC(F)=CC=2)=C1 YELJAOYXDLKMGA-UHFFFAOYSA-N 0.000 description 1
- GHHYIYWROJLOLU-UHFFFAOYSA-N (3-aminophenyl)-(4-methoxyphenyl)methanone Chemical compound C1=CC(OC)=CC=C1C(=O)C1=CC=CC(N)=C1 GHHYIYWROJLOLU-UHFFFAOYSA-N 0.000 description 1
- PRLOILJFLDVYKL-UHFFFAOYSA-N (3-aminophenyl)-(4-methylphenyl)methanone Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=CC(N)=C1 PRLOILJFLDVYKL-UHFFFAOYSA-N 0.000 description 1
- KZJVQORHPPEMBG-UHFFFAOYSA-N (5-amino-2-chlorophenyl)-phenylmethanone Chemical compound NC1=CC=C(Cl)C(C(=O)C=2C=CC=CC=2)=C1 KZJVQORHPPEMBG-UHFFFAOYSA-N 0.000 description 1
- JUZCVRZJGRPWJZ-UHFFFAOYSA-N 1,1,2,2,2-pentafluoroethanesulfonyl fluoride Chemical compound FC(F)(F)C(F)(F)S(F)(=O)=O JUZCVRZJGRPWJZ-UHFFFAOYSA-N 0.000 description 1
- KNVMLYXDZUGCQJ-UHFFFAOYSA-N 1,1,2,2-tetrafluoroethanesulfonyl chloride Chemical compound FC(F)C(F)(F)S(Cl)(=O)=O KNVMLYXDZUGCQJ-UHFFFAOYSA-N 0.000 description 1
- MDLKWDQMIZRIBY-UHFFFAOYSA-N 1-(dimethylamino)ethanol Chemical class CC(O)N(C)C MDLKWDQMIZRIBY-UHFFFAOYSA-N 0.000 description 1
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
- NVFNFJVPKWOWLY-UHFFFAOYSA-N 2,2,3,3-tetrafluoropropane-1-sulfonyl chloride Chemical compound FC(F)C(F)(F)CS(Cl)(=O)=O NVFNFJVPKWOWLY-UHFFFAOYSA-N 0.000 description 1
- DBNCQIZRJOFJHS-UHFFFAOYSA-N 3-benzoyl-1,1,2,2,3,4,4,4-octafluoro-N-phenylbutane-1-sulfonamide Chemical compound C=1C=CC=CC=1NS(=O)(=O)C(F)(F)C(F)(F)C(F)(C(F)(F)F)C(=O)C1=CC=CC=C1 DBNCQIZRJOFJHS-UHFFFAOYSA-N 0.000 description 1
- 241000220479 Acacia Species 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- 101001128694 Homo sapiens Neuroendocrine convertase 1 Proteins 0.000 description 1
- 101000601394 Homo sapiens Neuroendocrine convertase 2 Proteins 0.000 description 1
- 101000828971 Homo sapiens Signal peptidase complex subunit 3 Proteins 0.000 description 1
- 101000979222 Hydra vulgaris PC3-like endoprotease variant A Proteins 0.000 description 1
- 101000979221 Hydra vulgaris PC3-like endoprotease variant B Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 102100032132 Neuroendocrine convertase 1 Human genes 0.000 description 1
- 102100037732 Neuroendocrine convertase 2 Human genes 0.000 description 1
- 102100038946 Proprotein convertase subtilisin/kexin type 6 Human genes 0.000 description 1
- 101710180552 Proprotein convertase subtilisin/kexin type 6 Proteins 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- OMCWXFSQPKBREP-UHFFFAOYSA-N acetic acid;hydroiodide Chemical compound I.CC(O)=O OMCWXFSQPKBREP-UHFFFAOYSA-N 0.000 description 1
- MNZMECMQTYGSOI-UHFFFAOYSA-N acetic acid;hydron;bromide Chemical compound Br.CC(O)=O MNZMECMQTYGSOI-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 125000000751 azo group Chemical group [*]N=N[*] 0.000 description 1
- WIRUZQNBHNAMAB-UHFFFAOYSA-N benzene;cyclohexane Chemical compound C1CCCCC1.C1=CC=CC=C1 WIRUZQNBHNAMAB-UHFFFAOYSA-N 0.000 description 1
- SLUNEGLMXGHOLY-UHFFFAOYSA-N benzene;hexane Chemical compound CCCCCC.C1=CC=CC=C1 SLUNEGLMXGHOLY-UHFFFAOYSA-N 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- FXHWCQPYCGWOAW-UHFFFAOYSA-N bromomethanesulfonyl chloride Chemical compound ClS(=O)(=O)CBr FXHWCQPYCGWOAW-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000005661 deetherification reaction Methods 0.000 description 1
- 230000002951 depilatory effect Effects 0.000 description 1
- 150000008050 dialkyl sulfates Chemical class 0.000 description 1
- ZTCPYHGKJGSSPD-UHFFFAOYSA-N dichloromethanesulfonyl chloride Chemical compound ClC(Cl)S(Cl)(=O)=O ZTCPYHGKJGSSPD-UHFFFAOYSA-N 0.000 description 1
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 150000002222 fluorine compounds Chemical class 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000008570 general process Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- GTVRLHPVICIJFQ-UHFFFAOYSA-N hexane;tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl.CCCCCC GTVRLHPVICIJFQ-UHFFFAOYSA-N 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000031990 negative regulation of inflammatory response Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- XSXHWVKGUXMUQE-UHFFFAOYSA-N osmium dioxide Inorganic materials O=[Os]=O XSXHWVKGUXMUQE-UHFFFAOYSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000007655 standard test method Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- GRGCWBWNLSTIEN-UHFFFAOYSA-N trifluoromethanesulfonyl chloride Chemical compound FC(F)(F)S(Cl)(=O)=O GRGCWBWNLSTIEN-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/09—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton the carbon skeleton being further substituted by at least two halogen atoms
Definitions
- the invention relates to .Iadd.certain .Iaddend.haloalkanesulfonanilides .Iadd.(specifically certain haloalkylsulfonamidobenzophenones) .Iaddend.which have valuable pharmacological activity.Iadd., especially anti-inflammatory activity.Iaddend..
- Steroids having cortisone-like activity have heretofore been used for treatment of inflammatory, e.g. arthritic conditions. While these are effective, they have certain undesirable side effects. Consequently, there is a need for effective anti-inflammatory agents which are free of such disadvantages.
- novel and efficacious compounds of the present invention are non-steroidal in character, and their use does not entail side effects peculiar to steroid therapy.
- Of particular value in the anti-inflammatory compounds of the present invention is their relatively low toxicity, and they are well-tolerated by the gastrointestinal tract.
- a number of the new compounds also have anti-pyretic and analgesic activity. The pharmacological activities of these compounds have been elucidated by means of mammalian animal tests. .Iadd.
- the prior art also includes disclosures of certain haloalkanesulfonanilides, alleged to have protective action against the attack of textile pests, mold and bacteria. Representative of these disclosures are those contained in British Patents 738,758 and 856,452 and French Patent 1,188,591.
- British Patent 856,452 relates (inter alia) to haloalkyl (e.g. dichloromethanesulfonyl, chloroethanesulfonyl, trifluoro- or trichloromethanesulfonyl, trichloroethanesulfonyl-, etc.). Sulfonamides of amidodiphenylamines which are halogenated on one or both aromatic nuclei. It also refers to British Patent 738,758 and summarizes certain of its teachings.
- French Patent 1,188,591 has a disclosure somewhat similar to that of British Patent 738,758 but of comparable or less pertinence to the subject matter of the present case.
- the present invention contemplates providing a novel class of pharmacologically active compounds, especially compounds with anti-inflammatory activity.
- the invention further aims to provide compositions of the novel, active compounds which are suitable for administration for pharmacological purposes.
- compositions of the novel, active compounds which are suitable for administration for pharmacological purposes.
- processes for the preparation and use of the compounds of the invention for pharmacological purposes are processes for the preparation and use of the compounds of the invention for pharmacological purposes. Still other objectives of the invention will become apparent to those skilled in the art from reading the following disclosure.
- novel benzoylhaloalkanesulfonanilides of the invention (which may also be termed haloalkylsulfonamidobenzophenones) have the formula:
- R x is a haloalkyl group having up to four carbon atoms and at least one halogen atom bonded to the alpha carbon atom or if there is no halogen bonded to said alpha carbon atom, having at least 2 halogen atoms bonded to the beta carbon atoms, R is hydrogen, alkyl or alkenyl containing not more than three carbon atoms, or a pharmaceutically acceptable cation; each Y .Iadd.and Y' .Iaddend. is selected from hydroxy, halogen and alkyl, alkoxy, haloalkyl and haloalkoxy groups having up to 4 carbon atoms and n and n' are each 0-3.
- the various halogen atoms in an R x group can be the same or different
- the various Y .Iadd.and Y'.Iaddend. groups can be the same or different (regardless of whether they occur as substituents on the same ring or on the two different rings) and n and n' can be the same or different.
- n and n' can be the same or different.
- the rings will be unsubstituted, i.e. the compounds will have the formulae: ##SPC3##
- the compounds of Formula I have anti-inflammatory action when tested by standard test methods using animals, as described more particularly hereinafter.
- R x contains up to two carbon atoms are presently preferred, and those in which R x contains one carbon atom are most preferred.
- the compounds in which R x is perfluorinated also form a preferred group, particularly trifluoromethyl.
- the haloalkylsulfonamido group in the compounds of the invention is oriented meta to the carbonyl group.
- n and n' are zero, or in which one of them is zero and the other is one and the Y or Y' is hydroxy have outstanding anti-inflammatory activity and therefore also form a preferred class.
- R is alkyl
- R is methyl or ethyl
- Y and/or Y' are alkyl or alkoxy, it is preferred that the alkyl and alkoxy groups contain one carbon atom.
- Y and/or Y' are haloalkyl or haloalkoxy, it is preferred that they contain one carbon atom.
- the products of the present invention are effective anti-inflammatory agents and some also are analgesic and anti-pyretic agents.
- the anti-inflammatory activity can be conveniently demonstrated using assays designed to test the ability of these compounds to antagonize the local edema which is a characteristic of the anti-inflammatory response (rat foot edema test) and to inhibit the onset of the erythematous manifestation of inflammation (guinea pig erythema test).
- the edema test is performed on adult female rats.
- One group of 10 rats serves as non-medicated controls, while another group of 10 rats receives the test compound at various times prior to the induction of the edema, usually 15 minutes, one hour and/or 18 hours.
- the test compound is administered as a suspension in 4 percent aqueous solution of acacia.
- Edema is induced by the plantar injection of 0.5 percent carrageenin (0.1 ml./foot) into the right hind foot.
- the left hind foot receives a like volume of 0.9 percent saline solution.
- One hour later, the volume of each hind foot is determined plethysmographically.
- the edema is expressed as the increase in the volume of the edemogen injected foot (volume of the "edemogen foot” less the volume of the "saline foot”).
- the percent inhibition is calculated by dividing the mean increase in the edema of the edemogen foot of the medicated group by the mean increase in the non-medicated group, multiplied by 100.
- An active dose is that giving a statistically significant inhibition of the induced edema, usually about 30-35 percent inhibition.
- the erythema test is performed on adult, albino guinea pigs of either sex weighing 400-600 g. Hair is removed from the abdomen of the animals by a depilatory mixture the afternoon of the day prior to the day on which they are to be used. One group of 5 animals serves as non-medicated controls, while another group of 5 receives the test compound 30 minutes prior to direct exposure to ultraviolet light. For induction of erythema, the animal is restrained on a small animal board. Three circular sections (6-8 mm. in diameter) of the ventrolateral abdominal area of the animal are then exposed to a controlled amount of ultraviolet radiation. Two hours after exposure, the erythema is scored 0-5 on the basis of its intensity and completeness (full or partial circles).
- the maximal score per animal is 15.
- the percent inhibition is calculated on the basis of the mean score for the medicated group versus the non-medicated group.
- An active dose is taken to be that giving a statistically significant inhibition of the induced erythema, usually 35-40 percent inhibition. Modifications of this test include variation in the time and method of drug administration.
- the following compounds have been found to be effective anti-inflammatory agents (i.e., to have significant activity) at dosage levels of 100 mg./kg. or less in single doses:
- Aspirin which is very widely used as an anti-inflammatory agent, is only marginally active at 150 mg./kg. in the rat foot edema test.
- R x , n,n'.[.and Y.]. .Iadd.Y and Y' .Iaddend. are as previously defined and X represents a halogen atom, preferably chlorine or fluorine, or the corresponding anhydride grouping --OSO 2 R x (R x being defined as above).
- R x being defined as above.
- Approximately equivalent amounts of the reactants are brought together at temperatures most often ranging between about -15° and 150° C. If necessary or desirable, the reaction can be carried out in a pressure vessel.
- the reaction is preferably, but not necessarily, carried out in the presence of an acid acceptor such as the alkali or alkaline earth metal carbonates and bicarbonates or a tertiary amine such as pyridine, triethylamine or N,N-dimethylaniline.
- an acid acceptor such as the alkali or alkaline earth metal carbonates and bicarbonates or a tertiary amine such as pyridine, triethylamine or N,N-dimethylaniline.
- the amount of the acid acceptor can be varied widely; however, a 10 mole percent excess of that amount of base sufficient to bind the liberated strong acid (HX) is routinely employed.
- the condensation is usually conducted in the presence of an appropriate inert organic solvent.
- Typical solvents suitable for this purpose are methylene chloride, chloroform, carbon tetrachloride, benzene, toluene, bis(2-methoxyethyl) ether, acetonitrile, nitromethane, and the like.
- the product mixture can be extracted with a dilute aqueous base solution.
- the product, in the form of a salt which is usually soluble in the aqueous layer, is precipitated therefrom by addition of a mineral acid such as hydrochloric or sulfuric acid, and collected by filtration.
- the product mixture can be washed with aqueous hydrochloric acid, the solvent evaporated in vacuo, and the residue dissolved in a dilute aqueous base solution which is washed with dichloromethane and treated with decolorizing charcoal.
- the product, in the form of a salt is then isolated as described above.
- the product is generally obtained by dilution of the reaction mixture with water.
- the product a solid or oil, is separated and purified by conventional methods.
- the compounds prepared according to the foregoing procedures are crystalline solids purified, in general, by recrystallization from aqueous alcohol, trichloroethylene, hexane, benzene-hexane mixtures and the like. Elution chromatography has also been found to be a useful purification technique.
- R is hydrogen in the compounds of the invention
- this hydrogen is acidic in nature. Consequently, they readily form salts of alkali metals, alkaline earth metals, amines and the like.
- Pharmaceutically acceptable salts of these acidic compounds are included within the scope of Formula I, when R is a pharamaceutically acceptable cation.
- salts are readily prepared by adding the stoichiometric amount of the selected base in inert solvent solution to the acidic compound. The resulting solution is treated to remove the solvent, e.g. by evaporation under reduced pressure.
- the salts are conveniently used in making pharmaceutical preparations for administration of the compounds, e.g. in capsules for oral administration.
- Another method for the preparation of salts of the invention is the reaction of a salt of the invention with an organic or inorganic salt in a cation exchange reaction.
- R is alkyl or alkenyl
- R is hydrogen or a cation with an alkyl or alkenyl halide. This method for alkylation is known to the art.
- Suitable haloalkanesulfonylanhydrides and halides e.g. chlorides and fluorides
- halides e.g. chlorides and fluorides
- aminobenzophenones used in producing the compounds of the invention are generally described in the chemical literature or can be prepared from corresponding known substituted nitrobenzophenones by reduction. Any nitrobenzophenones or aminobenzophenones not specifically disclosed in the chemical literature are prepared by methods known in the literature for analogous compounds. Exemplary of such starting materials are:
- salts are made by the same process, substituting other alkali or alkaline earth metal hydroxides for sodium hydroxide.
- Amine salts are made using alcohol solutions of the stoichiometric amount of the amine, in a similar manner, e.g. the dimethylaminoethanol salt. Alternatively, water solutions of the amine may be used.
- a one liter flask fitted with reflux condenser was charged with 56.8 g. of 3-amino-4'-methoxybenzophenone (0.25 mole), 26.5 g. of N,N-dimethylaniline (0.30 mole), 37.8 g. of difluoromethanesulfonyl chloride (0.25 mole) and 350 ml. of methylene chloride.
- the mixture was heated at reflux temperature for 36 hours and then was extracted with dilute aqueous sodium hydroxide.
- Triethylamine was removed by evaporation, yielding an oil which was taken up in benzene.
- the benzene solution was washed with dilute hydrochloric acid and extracted with dilute sodium hydroxide. Acidification with hydrochloric acid affords a solid which was recrystallized from ethanol-water to give white, solid product, M.P. 95-97° C.
- Glacial acetic acid (20 ml.), 55% hydroiodic acid (7 ml.) and 3-benzoyl-4-methoxytrifluoromethanesulfonanilide (1.8 g., 5 mmole) were heated to reflux temperature and maintained at reflux for four hours. This reaction mixture was poured over ice, and the resulting mixture was extracted with dichloromethane. The dichloromethane layer was evaporated in vacuo to give a yellow solid. Recrystallization from benzene - cyclohexane gave light yellow 3-benzoyl-4-hydroxytrifluoromethanesulfonanilide, M.P. 133-136° C.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Benzoylhaloalkanesulfonanilides of the general type ##SPC1##
Wherein Rx is a haloalkyl group having up to four carbon atoms and at least one halogen atom bonded to the alpha carbon atom or if there is no halogen bonded to said alpha carbon atom, having at least 2 halogen atoms bonded to the beta carbon atom, R is hydrogen, alkyl or alkenyl containing not more than three carbon atoms, or a pharmaceutically acceptable cation; each Y .Iadd.and Y' .Iaddend.is selected from hydroxy, halogen and alkyl, alkoxy, haloalkyl and haloalkoxy groups having up to 4 carbon atoms and n and n' are each 0-3. These compounds and their salts have valuable pharmacological activity as anti-inflammatory agents. .Iadd.
Description
.[.This application is a continuation-in-part of the copending application Ser. No. 588,338, filed Oct. 21, 1966 and now abandoned, and Ser. No. 719,741, filed Apr. 8, 1968. .Iadd.
Application Ser. No. 832,824 was a continuation-in-part of the applications Ser. No. 588,338 filed Oct. 21, 1966 and now abandoned and Ser. No. 719,741 filed Apr. 8, 1968 and now abandoned. .Iaddend.
The invention relates to .Iadd.certain .Iaddend.haloalkanesulfonanilides .Iadd.(specifically certain haloalkylsulfonamidobenzophenones) .Iaddend.which have valuable pharmacological activity.Iadd., especially anti-inflammatory activity.Iaddend.. Steroids having cortisone-like activity have heretofore been used for treatment of inflammatory, e.g. arthritic conditions. While these are effective, they have certain undesirable side effects. Consequently, there is a need for effective anti-inflammatory agents which are free of such disadvantages.
The novel and efficacious compounds of the present invention are non-steroidal in character, and their use does not entail side effects peculiar to steroid therapy. Of particular value in the anti-inflammatory compounds of the present invention is their relatively low toxicity, and they are well-tolerated by the gastrointestinal tract. A number of the new compounds also have anti-pyretic and analgesic activity. The pharmacological activities of these compounds have been elucidated by means of mammalian animal tests. .Iadd.
The prior art also includes disclosures of certain haloalkanesulfonanilides, alleged to have protective action against the attack of textile pests, mold and bacteria. Representative of these disclosures are those contained in British Patents 738,758 and 856,452 and French Patent 1,188,591.
Thus, British Patent 738,758 discloses the formula
[hal.sub.x --R.sub.1.SO.sub.2.NH].sub.n --R
wherein R is said to include mono- or divalent polynuclear carbocyclic radicals wherein aromatic nuclei are linked either directly by a C--C-- linkage or by the bridging members --O--, --S--, --SO2 --, --SO--, --CH2 --, --CH=CH--, -- CO--, --N=N--, or they are condensed, R1 is an aliphatic hydrocarbon radical, x is an integer and n is 1 or 2 depending upon the valency of R. This is the only disclosure in the British Patent of any structure in which aromatic nuclei are linked by the bridging member --CO--, although theoretical lists of intermediates in the preparation of compounds containing other linking groups between aromatic rings are named as are compounds having structures in which two rings are bonded directly or are fused, or are connected through oxy, sulfonyl and azo groups.
British Patent 856,452 relates (inter alia) to haloalkyl (e.g. dichloromethanesulfonyl, chloroethanesulfonyl, trifluoro- or trichloromethanesulfonyl, trichloroethanesulfonyl-, etc.). Sulfonamides of amidodiphenylamines which are halogenated on one or both aromatic nuclei. It also refers to British Patent 738,758 and summarizes certain of its teachings.
French Patent 1,188,591 has a disclosure somewhat similar to that of British Patent 738,758 but of comparable or less pertinence to the subject matter of the present case.
Thus, the particular haloalkylsulfonamidobenzophenone anti-inflammatory agents of the present invention are not rendered obvious by the teachings of these foreign patents, individually or collectively.
The present invention contemplates providing a novel class of pharmacologically active compounds, especially compounds with anti-inflammatory activity. The invention further aims to provide compositions of the novel, active compounds which are suitable for administration for pharmacological purposes. Within the purview of the invention are processes for the preparation and use of the compounds of the invention for pharmacological purposes. Still other objectives of the invention will become apparent to those skilled in the art from reading the following disclosure.
The novel benzoylhaloalkanesulfonanilides of the invention (which may also be termed haloalkylsulfonamidobenzophenones) have the formula:
Formula I ##SPC2##
wherein Rx is a haloalkyl group having up to four carbon atoms and at least one halogen atom bonded to the alpha carbon atom or if there is no halogen bonded to said alpha carbon atom, having at least 2 halogen atoms bonded to the beta carbon atoms, R is hydrogen, alkyl or alkenyl containing not more than three carbon atoms, or a pharmaceutically acceptable cation; each Y .Iadd.and Y' .Iaddend. is selected from hydroxy, halogen and alkyl, alkoxy, haloalkyl and haloalkoxy groups having up to 4 carbon atoms and n and n' are each 0-3.
Unless otherwise specified, in the compounds of the invention, the various halogen atoms in an Rx group can be the same or different, the various Y .Iadd.and Y'.Iaddend. groups can be the same or different (regardless of whether they occur as substituents on the same ring or on the two different rings) and n and n' can be the same or different. When n and n' are both zero, the rings will be unsubstituted, i.e. the compounds will have the formulae: ##SPC3##
The compounds of Formula I have anti-inflammatory action when tested by standard test methods using animals, as described more particularly hereinafter.
Compounds of this invention wherein Rx contains up to two carbon atoms are presently preferred, and those in which Rx contains one carbon atom are most preferred. Compounds wherein the halogen in the Rx is fluorine and/or chlorine are presently preferred, particularly wherein the halogen therein is all fluorine (especially compounds in which Rx is HCF2 -- or H2 CF--). The compounds in which Rx is perfluorinated also form a preferred group, particularly trifluoromethyl.
Preferably in the foregoing groups and other compounds of the invention, the haloalkylsulfonamido group in the compounds of the invention is oriented meta to the carbonyl group.
The compounds in which n and n' are zero, or in which one of them is zero and the other is one and the Y or Y' is hydroxy have outstanding anti-inflammatory activity and therefore also form a preferred class.
When R is alkyl, it is preferred that R is methyl or ethyl. When Y and/or Y' are alkyl or alkoxy, it is preferred that the alkyl and alkoxy groups contain one carbon atom. Similarly when Y and/or Y' are haloalkyl or haloalkoxy, it is preferred that they contain one carbon atom.
The products of the present invention are effective anti-inflammatory agents and some also are analgesic and anti-pyretic agents. The anti-inflammatory activity can be conveniently demonstrated using assays designed to test the ability of these compounds to antagonize the local edema which is a characteristic of the anti-inflammatory response (rat foot edema test) and to inhibit the onset of the erythematous manifestation of inflammation (guinea pig erythema test).
The edema test is performed on adult female rats. One group of 10 rats serves as non-medicated controls, while another group of 10 rats receives the test compound at various times prior to the induction of the edema, usually 15 minutes, one hour and/or 18 hours. The test compound is administered as a suspension in 4 percent aqueous solution of acacia. Edema is induced by the plantar injection of 0.5 percent carrageenin (0.1 ml./foot) into the right hind foot. The left hind foot receives a like volume of 0.9 percent saline solution. One hour later, the volume of each hind foot is determined plethysmographically. The edema is expressed as the increase in the volume of the edemogen injected foot (volume of the "edemogen foot" less the volume of the "saline foot"). The percent inhibition is calculated by dividing the mean increase in the edema of the edemogen foot of the medicated group by the mean increase in the non-medicated group, multiplied by 100. An active dose is that giving a statistically significant inhibition of the induced edema, usually about 30-35 percent inhibition.
Leading references to this method are:
(1) Adamkiewicz et al., Canad. J. Biochem. Physio. 33: 332, 1955;
(2) Selye, Brit. Med. J. 2: 1129, 1949; and
(3) Winter, Proc. Soc. Exper. Biol. Med. 111: 544, 1962.
The erythema test is performed on adult, albino guinea pigs of either sex weighing 400-600 g. Hair is removed from the abdomen of the animals by a depilatory mixture the afternoon of the day prior to the day on which they are to be used. One group of 5 animals serves as non-medicated controls, while another group of 5 receives the test compound 30 minutes prior to direct exposure to ultraviolet light. For induction of erythema, the animal is restrained on a small animal board. Three circular sections (6-8 mm. in diameter) of the ventrolateral abdominal area of the animal are then exposed to a controlled amount of ultraviolet radiation. Two hours after exposure, the erythema is scored 0-5 on the basis of its intensity and completeness (full or partial circles). The maximal score per animal is 15. The percent inhibition is calculated on the basis of the mean score for the medicated group versus the non-medicated group. An active dose is taken to be that giving a statistically significant inhibition of the induced erythema, usually 35-40 percent inhibition. Modifications of this test include variation in the time and method of drug administration.
Leading references to this method are:
(1) Wilhelm, Schweiz, Med. Wschr. 25: 577, 1949, and
(2) Winder et al., Arch. Int. Pharmacodyn. 116: 261, 1958.
In the rat foot edema test and/or the guinea pig erythema test, the following compounds have been found to be effective anti-inflammatory agents (i.e., to have significant activity) at dosage levels of 100 mg./kg. or less in single doses:
3-benzoyldifluoromethanesulfonanilide,
3-benzoyldifluoromethanesulfonanilide, sodium salt,
3-benzoyl-4-hydroxytrifluoromethanesulfonanilide,
3-benzoylfluoromethanesulfonanilide,
3-(4-chloro-2-methylbenzoyl)trifluoromethanesulfonanilide,
N-methyl-3-benzoyltrifluoromethanesulfonanilide,
N-ethyl-3-benzoyltrifluoromethanesulfonanilide,
3-(4-methylbenzoyl)fluoromethanesulfonanilide,
3-(4 -chlorobenzoyl)difluoromethanesulfonanilide,
3-benzoyl-2,2,2-trifluoroethanesulfonanilide,
3-(4-methoxybenzoyl)difluoromethanesulfonanilide,
3-(4-methoxybenzoyl)fluoromethanesulfonanilide,
4-benzoyldifluoromethanesulfonanilide,
3-(2-hydroxybenzoyl)trifluoromethanesulfonanilide,
3-benzoyltrifluoromethanesulfonanilide,
4-benzoyltrifluoromethanesulfonanilide,
3-(4-methylbenzoyl)trifluoromethanesulfonanilide,
3-(4-methoxybenzoyl)trifluoromethanesulfonanilide,
3-(4-chlorobenzoyl)trifluoromethanesulfonanilide,
3-(3-chlorobenzoyl)trifluoromethanesulfonanilide,
3-(2-chlorobenzoyl)trifluoromethanesulfonanilide,
3-(2-methylbenzoyl)trifluoromethanesulfonanilide,
3-benzoylperfluoroethanesulfonanilide,
3-(4-fluorobenzoyl)trifluoromethanesulfonanilide,
3-benzoyl-4-chlorotrifluoromethanesulfonanilide,
3-benzoyl-(2-hydroperfluoroethane)sulfonanilide,
3-benzoyl-4-chlorodifluoromethanesulfonanilide,
4-chloro-3-(4-chlorobenzoyl)trifluoromethanesulfonanilide,
4-chloro-3-(4-fluorobenzoyl)trifluoromethanesulfonanilide,
3-(4-fluorobenzoyl)difluoromethanesulfonanilide,
3-benzoylchloromethanesulfonanilide,
4-chloro-3-(4-fluorobenzoyl)difluoromethanesulfonanilide, and
4-chloro-3-(4-chlorobenzoyl)difluoromethanesulfonanilide.
Aspirin, which is very widely used as an anti-inflammatory agent, is only marginally active at 150 mg./kg. in the rat foot edema test.
The compounds named hereinabove, and their salts are made by the general process described hereinbelow and as further specifically illustrated in the examples.
To produce the compounds of Formula I, wherein R is hydrogen, an aminobenzophenone is condensed with a haloalkylsulfonyl halide or anhydride according to the following scheme: ##SPC4##
wherein Rx, n,n'.[.and Y.]. .Iadd.Y and Y' .Iaddend. are as previously defined and X represents a halogen atom, preferably chlorine or fluorine, or the corresponding anhydride grouping --OSO2 Rx (Rx being defined as above). Approximately equivalent amounts of the reactants are brought together at temperatures most often ranging between about -15° and 150° C. If necessary or desirable, the reaction can be carried out in a pressure vessel. The reaction is preferably, but not necessarily, carried out in the presence of an acid acceptor such as the alkali or alkaline earth metal carbonates and bicarbonates or a tertiary amine such as pyridine, triethylamine or N,N-dimethylaniline. The amount of the acid acceptor can be varied widely; however, a 10 mole percent excess of that amount of base sufficient to bind the liberated strong acid (HX) is routinely employed.
The condensation is usually conducted in the presence of an appropriate inert organic solvent. Typical solvents suitable for this purpose are methylene chloride, chloroform, carbon tetrachloride, benzene, toluene, bis(2-methoxyethyl) ether, acetonitrile, nitromethane, and the like.
After reaction is complete, if the reaction solvent is not water miscible, the product mixture can be extracted with a dilute aqueous base solution. The product, in the form of a salt which is usually soluble in the aqueous layer, is precipitated therefrom by addition of a mineral acid such as hydrochloric or sulfuric acid, and collected by filtration. Alternatively the product mixture can be washed with aqueous hydrochloric acid, the solvent evaporated in vacuo, and the residue dissolved in a dilute aqueous base solution which is washed with dichloromethane and treated with decolorizing charcoal. The product, in the form of a salt is then isolated as described above.
If the reaction solvent is water miscible, the product is generally obtained by dilution of the reaction mixture with water. The product, a solid or oil, is separated and purified by conventional methods. The compounds prepared according to the foregoing procedures are crystalline solids purified, in general, by recrystallization from aqueous alcohol, trichloroethylene, hexane, benzene-hexane mixtures and the like. Elution chromatography has also been found to be a useful purification technique.
An additional and preferred method of obtaining the compounds of the invention in which Y .Iadd.or Y' .Iaddend.is hydroxy is by cleavage of the alkoxy group of the comparable sulfonanilides in which Y .Iadd.or Y' .Iaddend.is alkoxy. This can be done conveniently with hydrogen iodide-acetic acid mixtures. Alternatively, other known ether cleavage methods, e.g. hydrobromic acid-acetic acid, may be used.
When R is hydrogen in the compounds of the invention, this hydrogen is acidic in nature. Consequently, they readily form salts of alkali metals, alkaline earth metals, amines and the like. Pharmaceutically acceptable salts of these acidic compounds are included within the scope of Formula I, when R is a pharamaceutically acceptable cation.
Many of the salts are readily prepared by adding the stoichiometric amount of the selected base in inert solvent solution to the acidic compound. The resulting solution is treated to remove the solvent, e.g. by evaporation under reduced pressure. The salts are conveniently used in making pharmaceutical preparations for administration of the compounds, e.g. in capsules for oral administration. Another method for the preparation of salts of the invention is the reaction of a salt of the invention with an organic or inorganic salt in a cation exchange reaction.
Compounds of the invention wherein R is alkyl or alkenyl are readily prepared by the reaction of the compounds of the invention where R is hydrogen or a cation with an alkyl or alkenyl halide. This method for alkylation is known to the art.
Suitable haloalkanesulfonylanhydrides and halides (e.g. chlorides and fluorides) for use as starting materials in these procedures are known to the art, for example:
fluoromethanesulfonyl chloride,
fluorochloromethanesulfonyl chloride,
difluoromethanesulfonyl chloride,
dichloromethanesulfonyl chloride,
2,2,2-trifluoroethanesulfonyl chloride,
trifluoromethanesulfonyl chloride,
1,1,2,2-tetrafluoroethanesulfonyl chloride,
bromomethanesulfonyl chloride,
2,2,3,3-tetrafluoropropanesulfonyl chloride,
2-hydroperfluoropropanesulfonyl chloride,
and may others disclosed e.g. in U.S. Pat. No. 2,732,398.
The aminobenzophenones used in producing the compounds of the invention are generally described in the chemical literature or can be prepared from corresponding known substituted nitrobenzophenones by reduction. Any nitrobenzophenones or aminobenzophenones not specifically disclosed in the chemical literature are prepared by methods known in the literature for analogous compounds. Exemplary of such starting materials are:
5-amino-2-chlorobenzophenone,
3-amino-4'-fluorobenzophenone,
3-amino-5-bromobenzophenone,
3-amino-4'-ethylbenzophenone,
3-amino-2'-ethoxybenzophenone,
3-amino-4'-ethoxybenzophenone, etc.
The following examples are given for the purpose of further illustrating the present invention, but are not intended to limit the scope thereof. All melting and boiling points are uncorrected. All parts are by weight unless otherwise specified in the examples.
A 500 ml flask fitted with reflux condenser was charged with 8.7 g. of N,N-dimethylaniline (0.72 mole), a solution of 12.8 g. of 3-aminobenzophenone (0.065 mole) in 50 ml. of methylene chloride, 8.6 g. of fluoromethanesulfonyl chloride (0.065 mole, B.P. 138-141° C.) and 200 ml. of methylene chloride. The mixture was heated at reflux temperature overnight, then cooled, washed twice with 500 ml. portions of 10 percent hydrochloric acid and dried over anhydrous magnesium sulfate. The solvent was removed by evaporation leaving an oil that crystallized after 3 hours in the vacuum oven to afford relatively pure product, M.P. 116-119° C. This solid was taken up in 300 ml. of 10 percent aqueous sodium hydroxide. The solution was warmed, treated with activated carbon and acidified to pH 1 with concentrated hydrochloric acid. An oil formed initially but crystallized to give a solid, M.P. 115-117° C. This was recrystallized from 95 percent ethanol to give analytically pure product, M.P. 117-120° C.
Analysis.--Calculated for C14 H12 FNO3 S (percent): C, 57.3; H, 4.1. Found (percent): C, 57.7; H, 4.1.
A one liter flask fitted with reflux condenser was charged with 0.1 mole of 3-aminobenzophenone, 10 ml. of pyridine, 0.1 mole of difluoromethanesulfonyl chloride, and 400 ml. of benzene. The mixture was heated at 50-55° C. for 72 hours and then extracted with 10 percent aqueous sodium hydroxide. Acidification of the alkaline layer produced a solid which was recrystallized from trichloroethylene-hexane mixtures to afford analytically pure product, M.P. 99-100.5° C.
Analysis.--Calculated for C14 H11 F2 NO3 S (percent): C, 54.1; H, 3.6; N, 4.4. Found (percent): C, 53.9; H, 3.6; N, 4.4.
By the use of the general procedure of Examples 1 and 2 and the substitution of other haloalkanesulfonyl chlorides and other substituted aminobenzophenone starting materials, all of which are known, the following exemplary compounds are obtained:
__________________________________________________________________________
M.P., ° C.
Ex. (uncor-
No. rected)
__________________________________________________________________________
3 2-benzoyldifluoromethanesulfonanilide
79.5-81
4 3-(4-methylbenzoyl)difluoromethanesulfonanilide
119-121
5 3-(4-chlorobenzoyl)difluoromethanesulfonanilide
127-129
6 3-(4-methoxybenzoyl)fluoromethanesulfonanilide
116.5-118.5
7 3-benzoyl-4-chlorodifluoromethanesulfonanilide
99-102
8 3-benzoyl-4-chlorofluoromethanesulfonanilide
113-116
9 4-benzoyldifluoromethanesulfonanilide
124.5-126.5
10 2-benzoylfluoromethanesulfonanilide
74.5-75.5
11 3-(4-chlorobenzoyl)fluoromethanesulfonanilide
118-120
12 3-(4-n-butoxybenzoyl)fluoromethanesulfonanilide
113-117
13 3-(4-t-butylbenzoyl)fluoromethanesulfonanilide
102-105
14 3-(4-fluorobenzoyl)difluoromethanesulfonanilide
80-84
15 3-(4-fluorobenzoyl)fluoromethanesulfonanilide
127-129.5
16 3-(4-hydroxybenzoyl)difluoromethanesulfonanilide.sup.(1)
150-152
17 2-benzoyl-4-chlorodifluoromethanesulfonanilide
98-100
18 2-benzoyl-4-chlorofluoromethanesulfonanilde
88-89.5
19 3-benzoyl-(2-hydroperfluoroethane)sulfonanilide
80-80.5
20 3-benzoyl-(2-hydroperfluoro-n-propane)sulfonanilide
94-96
21 3-benzoylchloromethanesulfonanilide
95-97
22 4-chloro-3-(4-fluorobenzoyl)difluoromethane-
101-103
sulfonanilide.
23 4-chloro-3-(4-methylbenzoyl)difluoromethane-
77-79
sulfonanilide.
24 4-chloro-3-(4-chlorobenzoyl)difluoromethane-
81-83
sulfonanilide.
25 3-benzoyl-4-chlorochloromethanesulfonanilide
130-133
26 3-(4-methylbenzoyl)chloromethanesulfonanilide
118-119
27 3-(2-methylbenzoyl)chloromethanesulfonanilide
88-89
28 3-(2-methylbenzoyl)fluoromethanesulfonanilide
101-102
29 3-(2-chlorobenzoyl)chloromethanesulfonanilide
99-101
30 3-(2-chlorobenzoyl)fluoromethanesulfonanilide
123-125
31 3-(4-chlorobenzoyl)chloromethanesulfonanilide
149-150
32 3-benzoylperfluoro-n-butanesulfonanilide
.sup.(2)
__________________________________________________________________________
.sup.(1) Prepared by the method of Example 84 from the compound of Exampl
34.
.sup.(2) B.P. 186° C./0.09 mm.
To a solution of 12.21 g. of reagent grade sodium hydroxide (0.305 mole) in 300 ml. of water were added 95 g. of 3-benzoyldifluoromethanesulfonanilide (0.305 mole). The mixture was stirred until dissolution was complete and the solution had pH 7.2 (sensitive pH paper). Water was removed to give a yellow solid which was taken up in about 200 ml. of glyme and treated with activated charcoal. The clear solution was then added dropwise with vigorous stirring to 5 liters of ethyl ether. The crystalline salt was isolated by filtration, washed with 4 liters of ethyl ether and dried to give analytically pure product, M.P. (dec.) 235° C.
Analysis.--Calculated for C14 H10 F2 NaNO3 S (percent): C, 50.45; H, 3.05. Found: (percent): C, 50.6; H, 3.2.
Other salts are made by the same process, substituting other alkali or alkaline earth metal hydroxides for sodium hydroxide. Amine salts are made using alcohol solutions of the stoichiometric amount of the amine, in a similar manner, e.g. the dimethylaminoethanol salt. Alternatively, water solutions of the amine may be used.
A one liter flask fitted with reflux condenser was charged with 56.8 g. of 3-amino-4'-methoxybenzophenone (0.25 mole), 26.5 g. of N,N-dimethylaniline (0.30 mole), 37.8 g. of difluoromethanesulfonyl chloride (0.25 mole) and 350 ml. of methylene chloride. The mixture was heated at reflux temperature for 36 hours and then was extracted with dilute aqueous sodium hydroxide. After treatment with charcoal, acidification of the alkaline extract afforded a solid which was washed with hot heptane and recrystallized from carbon tetrachloridehexane mixtures to afford analytically pure product, M.P. 118-120° C.
Analysis.--Calculated for C15 H13 F2 NO4 S (percent): C, 52.8; H, 3.9; N, 4.1. Found (percent): C, 52.6; H, 3.9; N, 4.2.
A one liter flask was charged with 29.6 g. of 3-aminobenzophenone (0.15 mole), 9.2 g. of 2,2,2-trifluoroethanesulfonyl chloride (0.05 mole) and 250 ml. of methylene chloride. The mixture was allowed to stand for about an hour with occasional shaking. The reaction mixture was then washed with dilute hydrochloric acid to remove excess 3-aminobenzophenone, and the solvent was removed by evaporation to afford a solid product. Recrystallization of the solid from trichloroethylene and drying gave analytically pure product, M.P. 105.5-107° C.
Analysis.--Calculated for C15 H12 F3 NO3 S (percent): C, 52.5; H, 3.5; N, 4.1. Found (percent); C, 52.7; H, 3.7; N, 4.1.
A 500 ml. flask fitted with reflux condenser was charged with 10.5 g. of 3-amino-4'-methylbenzophenone (0.03 mole), 6.7 g. of N,N-dimethylaniline (0.055 mole), 6.6 g. of fluoromethanesulfonyl chloride (0.05 mole) and 150 ml. of methylene chloride. The reaction mixture was heated at reflux temperature for 20 hours. Methylene chloride was then removed by evaporation, and the residue was extracted with dilute aqueous sodium hydroxide. The alkaline extract was washed with ethyl ether, treated with charcoal and acidified. The precipitated solid was recrystallized from ethanol-water mixtures to give analytically pure product, M.P. 118-120° C.
Analysis.--Calculated for C15 H14 FNO3 S (percent): C, 58.7; H, 4.6; N, 4.6. Found (percent): C, 58.8; H, 4.8; N, 4.5.
A 300 ml. Parr pressure vessel was charged with 9.85 g. of 3-aminobenzophenone (0.05 mole), 150 ml. of triethylamine and 10.1 g. of perfluoroethanesulfonyl fluoride (0.05 mole). The mixture was heated at 90-100° C. for 24 hours.
Triethylamine was removed by evaporation, yielding an oil which was taken up in benzene. The benzene solution was washed with dilute hydrochloric acid and extracted with dilute sodium hydroxide. Acidification with hydrochloric acid affords a solid which was recrystallized from ethanol-water to give white, solid product, M.P. 95-97° C.
Analysis.--Calculated for C15 H10 F5 NO3 S (percent): C, 47.5; H, 2.7; N, 3.7. Found (percent): C, 47.7; H, 2.8; N, 3.7.
By the use of the general procedures of Examples 34-37 and the substitution of other haloalkanesulfonyl anhydride and halide starting materials, the following exemplary compounds are obtained.
______________________________________
Example No.:
______________________________________
38 3-benzoylfluorochloromethanesulfonani-
lide.
39 3-benzoyl-1,1,3-trihydroperfluoropro-
panesulfonanilide.
40 3-benzoyldichloromethanesulfonanilide.
41 3-benzoyl-perfluoroisopropanesulfon-
anilide.
42 3-benzoylbromomethanesulfonanilide.
______________________________________
Into a 3-necked, one liter flask equipped with stirrer, condenser, addition funnel, internal thermometer and nitrogen sweep were charged 59.8 g. of 3-aminobenzophenone (0.304 mole), 50.4 ml. of triethylamine and 400 ml. of chloroform. Trifluoromethanesulfonic anhydride was added slowly to the stirred mixture at 10-25° C. (ice-bath cooling). After stirring at room temperature for two hours, the solution was washed with dilute hydrochloric acid and then extracted with 10 percent aqueous sodium hydroxide. The aqueous extract was washed with chloroform until the washes were clear, clarified with charcoal, and acidified to pH 1 with concentrated hydrochloric acid. The product was collected by filtration, washed with water and dried. Recrystallization from hexane afforded analytically pure product, M.P. 99-101° C.
Analysis.--Calculated for C14 H10 F3 NO2 S (percent): C, 51.1; H, 3.1. Found (percent): C, 51.3; H, 3.2.
By use of the procedure of Example 43 and the substitution of other aminobenzophenone starting materials, the following exemplary compounds were obtained:
__________________________________________________________________________
M.P., ° C.
Ex. (uncor-
No. rected)
__________________________________________________________________________
44 2-benzoyltrifluoromethanesulfonanilide
98-100
45 4-benzoyltrifluoromethanesulfonanilide
136-137
46 3-(4-methylbenzoyl)trifluoromethanesulfonanilide
129.5-131.5
47 3-(4-methoxybenzoyl)trifluoromethanesulfonanilide
122.5-124.5
48 3-(4-fluorobenzoyl)trifluoromethanesulfonanilide
134-136
49 3-(4-chlorobenzoyl)trifluoromethanesulfonanilide
123.5-125.5
50 5-benzoyl-2-chlorotrifluoromethanesulfonanilide
102-103
51 3-benzoyl-5-chlorotrifluoromethanesulfonanilide
114-116
52 3-benzoyl-4-chlorotrifluoromethanesulfonanilide
106-108
53 3-benzoyl-2-chlorotrifluoromethanesulfonanilide
92-93
54 4-(2-chlorobenzoyl)trifluoromethanesulfonanilide
144.5-146.5
55 4-(3-chlorobenzoyl)trifluoromethanesulfonanilide
139-141
56 4-(4-chlorobenzoyl)trifluoromethanesulfonanilide
145-147
57 3-benzoyl-2-methyltrifluoromethanesulfonanilide
119-121
58 5-benzoyl-2-methyltrifluoromethanesulfonanilide
84-85
59 3-benzoyl-5-methyltrifluoromethanesulfonanilide
94-96
60 3-(3-methylbenzoyl)trifluoromethanesulfonanilide
91-93
61 2-(3-methylbenzoyl)trifluoromethanesulfonanilide
92-93
62 3-(2,5-dimethoxybenzoyl)trifluoro-
121.5-124
methanesulfonanilide.
63 4-chloro-3-(4-methylbenzoyl)trifluoro-
88-90
methanesulfonanilide.
64 4-chloro-3-(4-methoxybenzoyl)trifluoro-
89-90
methanesulfonanilide.
65 4-chloro-3-(4-chlorobenzoyl)trifluoro-
82-83
methanesulfonanilide.
66 4-chloro-3-(4-fluorobenzoyl)trifluoro-
133-134
methanesulfonanilide.
67 3-(2-methylbenzoyl)trifluoromethanesulfonanilide
92-93
68 4-chloro-2-(2-chlorobenzoyl)trifluoro-
86-88
methanesulfonanilide.
69 3-(3,4-dichlorobenzoyl)trifluoro-
146-147
methanesulfonanilide.
70 3-(2,5-dimethylbenzoyl)trifluoro-
85-86
methansulfonanilide.
71 3-(2,3-dimethylbenzoyl)trifluoro-
107-109
methanesulfonanilide.
72 3-benzoyl-4-methoxytrifluoromethanesulfonanilide
131-132
73 3-(2-methoxybenzoyl)trifluoromethanesulfonanilide
87-89
74 3-(2,6-dimethylbenzoyl)trifluoro-
113-114
methanesulfonanilide.
75 3-(4-chloro-2-methylbenzoyl)trifluoro-
135-137
methanesulfonanilide.
76 5-benzoyl-2-methoxytrifluoromethanesulfonanilide
87-89
77 3-benzoyl-4-bromotrifluoromethanesulfonanilide
131
78 3-(3,4-dimethylbenzoyl)trifluoro-
129
methanesulfonanilide.
79 3-(2,4-dimethylbenzoyl)trifluoro-
106-108
methanesulfonanilide.
80 3-(4-ethylbenzoyl)trifluoromethanesulfonanilide
90-91
81 3-(3-fluorobenzoyl)trifluoromethanesulfonanilide
96-98
82 3-benzoyl-2-methoxytrifluoromethanesulfonanilide
132-133
83 3-benzoyl-5-methoxytrifluoromethanesulfonanilide
89-91
__________________________________________________________________________
Glacial acetic acid (20 ml.), 55% hydroiodic acid (7 ml.) and 3-benzoyl-4-methoxytrifluoromethanesulfonanilide (1.8 g., 5 mmole) were heated to reflux temperature and maintained at reflux for four hours. This reaction mixture was poured over ice, and the resulting mixture was extracted with dichloromethane. The dichloromethane layer was evaporated in vacuo to give a yellow solid. Recrystallization from benzene - cyclohexane gave light yellow 3-benzoyl-4-hydroxytrifluoromethanesulfonanilide, M.P. 133-136° C.
Analysis.--Calculated for C14 H10 F3 NO4 S: (percent): C, 48.7; H, 2.9; N, 4.1. Found (percent): C, 49.1; H, 2.9; N, 4.0.
By use of the general procedure of Example 84 and the substitution of other benzoylmethoxysulfonanilides, the following exemplary compounds were obtained:
__________________________________________________________________________
Melting
Ex. point
No. (in ° C.)
__________________________________________________________________________
85 3-(4-hydroxybenzoyl)trifluoromethanesulfonanilide
156-158
86 3-(3-hydroxybenzoyl)trifluoromethanesulfonanilide
169-172
87 5-benzoyl-2-hydroxytrifluoromethanesulfonanilide
178-181
88 3-benzoyl-5-hydroxytrifluoromethanesulfonanilide
128-130
89 3-benzoyl-2-hydroxytrifluoromethanesulfonanilide
86-88
90 3-(2-hydroxybenzoyl)trifluoromethanesulfonanilide
131-133
__________________________________________________________________________
Sodium carbonate (6.89 g., 0.082 mole) was dissolved in distilled water (70 ml.) and 3-benzoyltrifluoromethanesulfonanilide (27.0 g., 0.082 mole) was added in small portions. Water (30 ml.) was added and the solution as stirred for three hours. The solution was filtered and the filtrate was evaporated to dryness in vacuo. The solid was dissolved in ethanol, treated with decolorizing charcoal and filtered. The filtrate was evaporated to dryness in vacuo, and the solid sodium 3-benzotrifluoromethanesulfonanilide was dried.
Analysis.--Calculated for C14 H9 F3 NNaO3 S (percent): C, 48.0; H, 2.16. Found (percent): C, 48.0; H, 2.8.
Sodium 3-benzoyltrifluoromethanesulfonanilide (20 g., 57 mmole), acetone (250 ml.) and ethyl iodide (11.7 g., 75 mmole) were heated to reflux and maintained at reflux temperature for 1 day. The reaction mixture was evaporated to remove solvent and the oil obtained was dissolved in chloroform. The solution was washed twice with 10 percent sodium hydroxide, twice with water and dried over magnesium sulfate; then treated with decolorizing charcoal and filtered. The solvent was removed in vacuo and the liquid product was distilled through a molecular still to give a light yellow liquid, N-ethyl-3-benzoyltrifluoromethanesulfonanilide, column temperature 170° C., pressure 1 × 10- 5 mm. of mercury.
Analysis.--Calculated for C16 H14 F3 NO3 S (percent): C, 53.8; H, 3.95. Found (percent): C, 53.8; H, 4.0.
By the use of the general procedure of Example 91 and the substitution of other reactive alkyl halides or dialkyl sulfates the following exemplary compounds are obtained:
______________________________________
Example No.:
______________________________________
92 N-methyl-3-benzoyltrifluoromethanesul-
fonanilide.
93 N-n-propyl-3-benzoyltrifluoromethanesul-
fonanilide.
94 N-allyl-3-benzoyltrifluoromethanesulfon-
anilide.
95 N-methyl-3-benzoyldifluoromethanesul-
fonanilide.
96 N-methyl-3-benzoyl-4-hydroxytrifluoro-
methanesulfonanilide.
97 N-methyl-3-benzoylfluorochloromethane-
sulfonanilide.
98 N-methyl-3-(4-chlorobenzoyl)trifluorometh-
anesulfonanilide.
99 N-methyl-3-benzoyl-4-methoxytrifluoro-
methanesulfonanilide.
100 N-methyl-3-benzoylchloromethanesulfon-
anilide.
101 N-ethyl-3-benzoylchloromethanesulfonani-
lide.
______________________________________
Additional compounds of the invention prepared by the foregoing general procedures are as follows:
__________________________________________________________________________
Melting
Ex. point
No. (in ° C.)
__________________________________________________________________________
102 3-(3-trifluoromethylbenzoyl) trifluoromethanesul-
86-88
fonanilide.
103 3-(2-trifluoromethylbenzoyl)trifluoromethanesul-
110-111
fonanilide.
104 3-(4-trifluoromethoxybenzoyl)trifluoromethanesul-
107-109
fonanilide.
__________________________________________________________________________
Claims (1)
- What is claimed is: .[.1. A compound of the formula: ##SPC5##wherein Rx is a haloalkyl group having up to four carbon atoms and at least one halogen atom bonded to the alpha carbon atom or if there is no halogen bonded to said alpha carbon atom, having at least 2 halogen atoms bonded to the beta carbon atom, R is hydrogen, alkyl or alkenyl containing not more than three carbon atoms, or a pharmaceutically acceptable cation; each Y is selected from hydroxy, halogen and alkyl, alkoxy, haloalkyl and haloalkoxy groups having up to 4 carbon atoms and n and n' are each 0-3..]. .[.2. A compound according to claim 1 wherein the halogen atoms in the Rx group are all fluorine..]. .[.3. A compound according to claim 2 wherein Rx is a perfluoroalkyl group..]. .[.4. N-methyl 3-benzoyltrifluoromethanesulfonanilide according to claim 3..]. .[.5. 3-benzoyl-4-hydroxytrifluoromethanesulfonanilide according to claim 3..]. .[.6. A compound according to claim 1, in which the haloalkanesulfonamido group is in meta orientation to the carbonyl group..]. .[.7. A compound according to claim 6, in which Rx is HCF2 --..]. .[.8. 3-benzoyldifluoromethanesulfonanilide according to claim 7..]. .[.9. The sodium salt of 3-benzoyldifluoromethanesulfonanilide according to claim 7..]. .[.10. A compound according to claim 6, in which Rx is H2 CF--..]. .[.11. 3-benzoylfluoromethanesulfonanilide according to claim 10..]. .[.12. A compound of the formula: ##SPC6##wherein Rx is a haloalkyl group having up to two carbon atoms and at least one halogen atom bonded to the alpha carbon atom or if there is no halogen bonded to said alpha carbon atom, having at least two halogen atoms bonded to the beta carbon atom, provided that the halogen in Rx is selected from chlorine and fluorine; R is hydrogen, methyl, ethyl or a pharmaceutically acceptable cation; each Y is selected from hydroxy, halogen, methyl and methoxy; and n and n' are each 0-1..]. .[.13. A compound according to claim 12 of the formula: ##SPC7##.]. .[.14. A compound according to claim 2 wherein Rx is trifluoromethyl..]. .Iadd. 15. A compound of the formula ##SPC8##wherein Rx is a fluoromethyl group, R is hydrogen, alkyl or alkenyl containing not more than three carbon atoms, or a pharmaceutically acceptable cation; each Y and Y' is selected from hydroxy, halogen and alkyl, alkoxy, haloalkyl and haloalkoxy groups having up to 4 carbon atoms and n and n' are each 0-3. .Iaddend..Iadd. 16. A compound according to claim 15 wherein Rx is CF3 --. .Iaddend. .Iadd. 17. N-methyl 3-benzoyltrifluoromethanesulfonanilide according to claim 16. .Iaddend..Iadd. 18. 3-Benzoyl-4-hydroxytrifluoromethanesulfonanilide according to claim 16. .Iaddend..Iadd. 19. A compound according to claim 15 in which Rx is HCF2 --. .Iaddend..Iadd. 20. 3-Benzoyldifluoromethanesulfonanilide according to claim 19. .Iaddend..Iadd. 21. The sodium salt of 3-benzoyldifluoromethanesulfonanilide according to claim 19. .Iaddend..Iadd. 22. A compound according to claim 15 in which Rx is H2 CF--. .Iaddend..Iadd. 23. 3-Benzoylfluoromethanesulfonanilide according to claim 22. .Iaddend..Iadd. 24. A compound according to claim 15 of the formula: ##SPC9##wherein R is hydrogen, methyl, ethyl or a pharmaceutically acceptable cation. .Iaddend.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US05/632,572 USRE29032E (en) | 1969-06-12 | 1975-11-17 | 3-Benzoylfluoro-methanesulfonanilides |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83282469A | 1969-06-12 | 1969-06-12 | |
| US05/632,572 USRE29032E (en) | 1969-06-12 | 1975-11-17 | 3-Benzoylfluoro-methanesulfonanilides |
Related Parent Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US58833866A Continuation-In-Part | 1966-10-21 | 1966-10-21 | |
| US71974168A Continuation-In-Part | 1968-04-08 | 1968-04-08 | |
| US83282469A Reissue | 1969-06-12 | 1969-06-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| USRE29032E true USRE29032E (en) | 1976-11-09 |
Family
ID=27091669
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US05/632,572 Expired - Lifetime USRE29032E (en) | 1969-06-12 | 1975-11-17 | 3-Benzoylfluoro-methanesulfonanilides |
Country Status (1)
| Country | Link |
|---|---|
| US (1) | USRE29032E (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4321081A (en) | 1980-04-11 | 1982-03-23 | Sumitomo Chemical Company, Limited | Ortho-(trifluoromethylsulfonamido)benzamides as herbicides |
| US5034417A (en) * | 1987-05-29 | 1991-07-23 | Fujisawa Pharmaceutical Co., Ltd. | New alkanesulfonanilide derivatives, processes for preparation thereof and pharmaceutical composition comprising the same |
| WO2002065979A3 (en) * | 2001-02-20 | 2003-02-20 | Astrazeneca Ab | (diazolo-pyridinyl)-pyrimidines for use in treatment of cns disorders and diabetes |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2075359A (en) * | 1930-10-16 | 1937-03-30 | Du Pont | Insecticide |
| GB738758A (en) * | 1951-09-10 | 1955-10-19 | Bayer Ag | Protective agents against textile pests, mould and bacteria |
| FR1188591A (en) * | 1956-12-08 | 1959-09-23 | Bayer Ag | Protective agents against parasites of textile materials and against attack by bacteria and molds |
| GB856452A (en) * | 1957-06-27 | 1960-12-14 | Bayer Ag | Protective agents against textile pests, mould and bacteria |
-
1975
- 1975-11-17 US US05/632,572 patent/USRE29032E/en not_active Expired - Lifetime
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2075359A (en) * | 1930-10-16 | 1937-03-30 | Du Pont | Insecticide |
| GB738758A (en) * | 1951-09-10 | 1955-10-19 | Bayer Ag | Protective agents against textile pests, mould and bacteria |
| FR1188591A (en) * | 1956-12-08 | 1959-09-23 | Bayer Ag | Protective agents against parasites of textile materials and against attack by bacteria and molds |
| GB856452A (en) * | 1957-06-27 | 1960-12-14 | Bayer Ag | Protective agents against textile pests, mould and bacteria |
Non-Patent Citations (2)
| Title |
|---|
| Rossi et al., "Annali di Chimica," vol. 56(6), June 1966, p. 733. |
| Rossi et al., "Annali di Chimica," vol. 56(6), June 1966, p. 733. * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4321081A (en) | 1980-04-11 | 1982-03-23 | Sumitomo Chemical Company, Limited | Ortho-(trifluoromethylsulfonamido)benzamides as herbicides |
| US5034417A (en) * | 1987-05-29 | 1991-07-23 | Fujisawa Pharmaceutical Co., Ltd. | New alkanesulfonanilide derivatives, processes for preparation thereof and pharmaceutical composition comprising the same |
| WO2002065979A3 (en) * | 2001-02-20 | 2003-02-20 | Astrazeneca Ab | (diazolo-pyridinyl)-pyrimidines for use in treatment of cns disorders and diabetes |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4258058A (en) | Phenoxyalkylcarboxylic acid compounds and thrombocyte-aggregation inhibition | |
| US3781328A (en) | Phenoxy-alkyl-carboxylic acid compounds | |
| DE69417885T2 (en) | N-ACYLSULFAMIC ACID ESTERS (OR THIOESTER), N-ACYLSULFONAMIDES, AND N-SULFONYLCARBAMIC ACID ESTERS (OR THIOESTERS) AS HYPERCHOLESTEROLEMIC AGENTS | |
| US3840597A (en) | Substituted 2-phenoxy alkane-sulfonanilides | |
| JP5450105B2 (en) | Biphenyl-4-yl-sulfonic acid arylamides and their use as therapeutic agents | |
| ES2223116T3 (en) | AMINOBENZOPHENONS AS INHIBITORS OF INTERLEUCINE AND TNF. | |
| EP0028063A1 (en) | Phenol derivatives, processes for their preparation and pharmaceutical compositions containing them | |
| WO2004045511A2 (en) | Non-steroidal farnesoid x receptor modulators | |
| US3576866A (en) | Benzoylhaloalkanesulfonanilides | |
| US6903114B2 (en) | Derivatives of naphthalene with COMT inhibiting activity | |
| IL42640A (en) | Substituted 2'-phenoxyalkane-sulfonanilides | |
| AU641676B2 (en) | Antiarrhythmic tertiary amine-alkenyl-phenyl-alkanesulfonamides | |
| JPH02270855A (en) | anti-inflammatory aryl compounds | |
| SU664561A3 (en) | Method of obtaining 2-(4-acylamino-alkyl)-phenoxy/-alkylcarboxylic acid derivatives or salts thereof | |
| USRE29032E (en) | 3-Benzoylfluoro-methanesulfonanilides | |
| JPH03215456A (en) | Acylphenol derivative | |
| JPH05221980A (en) | Acetylene compound | |
| US3725451A (en) | Substituted benzoylhaloalkanesulfonanilides | |
| US3758688A (en) | Substituted sulfonanilides in the treatment of inflammation | |
| US3663708A (en) | N-aryl-n-fluoroalkylsulfonyl carbamates | |
| WO1989001330A2 (en) | W-arylsulphonamidoalkanoic acids for treatment of thromboxane mediated diseases | |
| NO166911B (en) | BACTERICID AND FUNGICID AGENTS ON THE BASIS OF TRIBUTYLTIN COMPOUNDS AND PROCHLORAZ, AND APPLICATIONS THEREOF. | |
| US3689523A (en) | Substituted haloalkanesulfonanilides | |
| AU727216B2 (en) | Sulfonamide-substituted compounds, processes for their preparation, their use as a medicament or diagnostic, and medicament comprising them | |
| JP7426756B2 (en) | Thiobenzopyran compounds and their use in the preparation of drugs for the treatment of rheumatoid arthritis |